Skip to main content
. Author manuscript; available in PMC: 2009 Jan 30.
Published in final edited form as: Vaccine. 2007 Dec 4;26(5):664–676. doi: 10.1016/j.vaccine.2007.11.045

Figure 4.

Figure 4

Pathogenesis in SCID mice infected intra-nasally with wtVACV or VACV E3L mutants. Groups of five female SCID mice were infected intra-nasally with either wtVACV or the indicated VACV E3L mutants at the indicated doses. Mice were weighed every other day and monitored for 1 month for signs of illness. Percent survival is presented in panel A, and weight loss is presented in panel B. For panel B, lines ending prematurely indicate mortality.